Zacks' Voice of the People Highlights Opportunities with Dendreon Corp.

CHICAGO--(Business Wire)--
Zacks highlights commentary from People and Picks Trader "MackTheKnife".

For more Voice of the People, visit http://at.zacks.com/?id=5851

Featured Post

DNDN Presents Data on Provenge MOA

IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) clinical-trial data
showing evidence of immune responses in patients treated with Provenge and
supporting its proposed mechanism of action were presented by the Dendreon Corp.
(Nasdaq: DNDN) at the American Association for Cancer Research's 101st Annual
Meeting, which began Saturday and ends today in Washington.

The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug
User Fee Act (PDUFA) date of May 1 to Dendreon's amended biologics license
application for Provenge, which the company is seeking to have licensed for men
with metastatic castrate-resistant prostate cancer (CRPC). Should the FDA follow
the data this time around, Provenge would be the first product in the new
therapeutic class known as active cellular immunotherapies.

In a press release today, David Urdal, senior vice president and chief
scientific officer of Dendreon, notes: "These data strongly support our
understanding of the proposed mechanism of action of active cellular
immunotherapies. There is clear evidence that Provenge primes the T-cell
component of the immune system in vivo through ex vivo activation, generating a
successful and long-lasting immune response."

About the Zacks Community

In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking
website where members of the Zacks community can test their strategies and share
ideas with other members. Each user is scored on the accuracy of his or her
picks, and top users are rewarded with free products from Zacks. Registration is
free. To learn more about People And Picks, visit http://at.zacks.com/?id=5957

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in
1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns
in stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking system;
the Zacks Rank, which continues to outperform the market by nearly a 3:1 margin.
The best way to unlock the profitable stock recommendations and market insights
of Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to
be worth your time! Register for your free subscription to Profit From the Pros
by going to http://at.zacks.com/?id=5958.

Follow us on Twitter: http://twitter.com/ZacksInvestment

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such
affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should
always research companies and securities before making any investments. Nothing
herein should be construed as an offer or solicitation to buy or sell any
security.

Brent Billock
People & Picks Manager
Zacks.com
312-265-9307
pandp@zacks.com
Visit: www.Zacks.com

Copyright Business Wire 2010